Drug intelligence / Profile preview

tecotabart

Development stage: Discontinued
Lead developer: LaNova Medicines
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Tecotabart (LM-102) is a recombinant humanized monoclonal antibody that targets the tumor-associated antigen claudin 18.2 (CLDN18.2), an isoform of claudin-18 highly expressed in certain solid tumors, particularly gastrointestinal cancers. By binding to CLDN18.2 on tumor cells, LM-102 is designed to stimulate immune-mediated antitumor activity through mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The drug was developed by LaNova Medicines and entered early-phase clinical trials for patients with advanced solid tumors expressing CLDN18.2, but its development has since been terminated[1][2][5][8].

Other names: tecotabart

Targets

Claudin 18.2

Beyond the preview

Go deeper on tecotabart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tecotabart.

Explore the full profile